文献速递冠心病外科

冠状动脉旁路移植术中传输时间血流测量:桥血管通畅性与临床结局

Coronary Artery Bypass Grafting Transit Time Flow Measurement: Graft Patency and Clinical Outcomes.
PubMed 文献 · Ann Thorac Surg · 2020-12-23

该研究为ROOBY试验亚分析,评估冠状动脉旁路移植术中使用传输时间血流测量(TTFM)对桥血管通畅性和长期临床结局的影响。TTFM组1067例,非TTFM组501例。TTFM组1年FitzGibbon A通畅率83%,非TTFM组78%(P<.01);TTFM组桥血管闭塞比例更低(29% vs 38%,P=.01)。5年主要不良心脏事件率两组分别为30%和25%(P=.06)。结论认为TTFM使用与桥血管通畅性和临床结局的关联尚不确定。

要点

  • TTFM组1年桥血管通畅率83%,高于非TTFM组的78%(P<.01)。
  • TTFM组桥血管闭塞比例29%,低于非TTFM组的38%(P=.01)。
  • 5年主要不良心脏事件率两组差异无统计学意义(30% vs 25%,P=.06)。

核心结论

  • TTFM使用与桥血管通畅性和临床结局的关联尚不确定,需未来随机研究进一步验证。

研究设计与样本

  • 本研究为随机对照试验ROOBY的子分析,评估TTFM使用情况及其对桥血管通畅性和长期临床结局的影响。
  • TTFM组1067例,非TTFM组501例;TTFM组中位使用率在18个退伍军人医疗中心为79%(四分位距41%至98%),在48名外科医生中为74%(四分位距13%至98%)。

主要发现

  • TTFM组与非TTFM组年龄(63±8.5岁 vs 62±8岁,P=.30)和估计30天死亡风险(1.8±1.7 vs 1.9,P=.53)可比。
  • 1年FitzGibbon A通畅率TTFM评估桥血管为83%(1600/1988),非TTFM评估桥血管为78%(629/803),P<.01。
  • TTFM组桥血管闭塞患者比例29%,非TTFM组38%,P=.01。
  • 5年主要不良心脏事件率TTFM组30%,非TTFM组25%,P=.06;死亡14% vs 11%(P=.06),心肌梗死12% vs 8.8%(P=.07),血运重建13% vs 12%(P=.62)。

临床怎么用

  • TTFM可用于术中评估桥血管质量,可能有助于提高桥血管通畅性,但对长期临床结局的获益尚未明确。

局限性

  • 本研究为ROOBY试验亚分析,TTFM使用非随机分配,可能存在患者风险因素和实践差异的混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This subanalysis of the Randomized On-Off Bypass (ROOBY) trial examined transit time flow measurement (TTFM) use and its impact on graft patency and long-term clinical outcomes after coronary artery bypass graft surgery. METHODS: Use of TTFM for ROOBY centers and surgeons was assessed. Comparative patient outcomes based on TTFM use included 1-year graft patency and 1-year and 5-year major adverse cardiac events: all-cause mortality, nonfatal myocardial infarction, and revascularization (percutaneous coronary intervention or repeat coronary artery bypass graft surgery). RESULTS: Transit time flow measurement was used in 1067 patients (TTFM group) and not used in 501 patients (non-TTFM group); of the TTFM group, median percentage TTFM use was 79% (interquartile range, 41% to 98%) among 18 Veterans Affairs Medical Centers, and 74% (interquartile range, 13% to 98%) among 48 surgeons. Patients were comparable in age (63 ± 8.5 years TTFM vs 62 ± 8 years non-TTFM, P = .30) and estimated 30-day mortality risk (1.8 ± 1.7 TTFM vs 1.9 non-TTFM, P = .53). One-year FitzGibbon A patency was 83% (1600 of 1988 grafts) for TTFM assessed grafts and 78% (629 of 803) for non-TTFM assessed grafts (P < .01). Fewer TTFM patients had an occluded graft (29%, vs 38% non-TTFM; P = .01). Comparing TTFM patients with non-TTFM patients, 5-year major adverse cardiac event rates were 30% vs 25% (P = .06). Individual component rates were 14% vs 11% for death (P = .06), 12% vs 8.8% for myocardial infarction (P = .07), and 13% vs 12% for revascularization (P = .62). CONCLUSIONS: The association of TTFM use with graft patency and clinical outcome is uncertain. Future randomized studies that account for patient risk factors and practice variation would help address this knowledge gap.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Quin JA, Noubani M, Rove JY, et al. Coronary Artery Bypass Grafting Transit Time Flow Measurement: Graft Patency and Clinical Outcomes. Ann Thorac Surg. 2020. PMID: 33359134. doi:10.1016/j.athoracsur.2020.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。